Experimental drug targets gene driving severe seizures in children
Researchers at the Fralin Biomedical Research Institute are developing a targeted KCNT1 inhibitor that has shown early promise in reducing seizures in preclinical models.
List view / Grid view
Researchers at the Fralin Biomedical Research Institute are developing a targeted KCNT1 inhibitor that has shown early promise in reducing seizures in preclinical models.
Researchers at POSTECH have developed a new 3D brain model that closely mimics the structure and function of human brain tissue – marking a major advance in early disease detection.
Chiesi Group and Key2Brain have signed a global license agreement to develop two blood-brain barrier-crossing enzyme replacement therapies for alpha-mannosidosis and Krabbe disease – with the aim to help patients with limited treatment options.
Fauna Bio has launched Fauna Brain™, a powerful new AI platform that leverages the company’s expertise in comparative genomics to accelerate drug target discovery.
How do new cancer drugs make it to patients? This episode uncovers the challenges, successes, and AI advancements driving oncology treatments from preclinical screening to clinical trials.
DenovAI has unveiled a powerful AI-driven protein design platform capable of creating new, functional synthetic proteins from scratch - marking a big step forward for drug discovery.
Researchers at Southern Medical University have developed a self-propelled ferroptosis nanoinducer that penetrates deeper into tumour tissues - offering a new strategy for safer and more effective cancer treatment.
James Atwood, COO of Opentrons, shares how accessible lab automation is helping research teams tackle tighter budgets, faster timelines and complex discovery workflows.
A practicing surgeon turned biotech CEO is developing a novel pain medicine that could sidestep the failures of both opioids and paracetamol.
SynaptixBio has selected its lead drug candidate, SB H-19642, for clinical trials to treat H-ABC - a rare, fatal neurodegenerative disease with no current cure.
Centauri Therapeutics has published data showing that CTX-09’s ability effectively clears drug-resistant Gram-negative bacteria through a novel dual mechanism, marking a promising development for new infection therapies.
A new study at Science Tokyo has developed patient-derived organoids to better understand and combat resistance in oesophageal squamous cell carcinoma (ESCC).
Researchers at the University of Alabama have identified reelin, a glycoprotein known for its role in brain development, as a key regulator of neurons in the brain's reward centre, potentially making way for targeted therapies against cocaine use.
Stanford scientists have successfully grown heart and liver organoids that include functioning blood vessels. This breakthrough overcomes a major size and maturity barrier, which could advance disease modelling and regenerative therapies in the future.
Discover how Domain Therapeutics is using its deep knowledge of GPCR biology to create novel therapeutics with the potential to combat inflammatory diseases such as atopic dermatitis, IBD and arthritis.